Number Three, Of Four: Lilly's Tripled Q1 Lobby Spend ('23 To '25) Is Driven By The Explosion Of Its Weight Loss Franchises...

That is decidedly good news (for Lilly shareholders) -- it is making an investment, in lobbying, to protect both its patent positions on the drugs -- and keep them listed as covered -- through Medicare / Medicaid -- and private insurance plans, where medical necessity is demonstrated. [We remain unsure as to what the long term side effects might be, from being on the jabs for years and years. Time will tell.]

In any event, next up -- and the final installment -- will be Amgen. Also a company that is bumping up its spending. But here is the Lilly rundown:

. . .Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil; US Tariffs. . . .

Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Policy matters related to Artificial Intelligence in health care. . . .

Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement, coverage and value; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease. . . .

Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value, access and quality. . . .

Pharmaceutical intellectual property issues. . . .

Implementation and extension of the Tax Cuts and Jobs Act; Domestic manufacturing tax incentives; Expensing of research and development costs; Global minimum tax; Pension and retirement benefit issues; round-tripping. . . .

Hospital discounts; 340B program; Prescription drug value, access, quality and compliance with Drug Quality and Safety Act. . . .

That last bolded bit is the Lilly litigation / legislation / lobbying campaign. . . to keep various compounders (some of which are perfectly reputable) from undercutting the weight loss franchise drug's premium pricing, in the US -- via supposed supply shortages. Now you know.

Onward now, into a Middle East driven primarily by corruption and commerce, it seems. [This present "Tangerine World" (normalizing brutal Syria) bears scant resemblance to the the not so long ago time, when Cy Vance had medical device companies pleading guilty to felonies -- simply for providing life-saving IV solutions bags -- to hospitals, for sick children, inside Syria.] Wow.

नमस्ते